Brain metastasis from renal cell carcinoma - Presentation, recurrence, and survival
Brain metastasis from renal cell carcinoma - Presentation, recurrence, and survival
复制标题
DOI：
10.1002/cncr.23769
复制
发表时间：
2008-10-01
期刊：
影响因子：
6.2
通讯作者：
Belldegrun, Arie S.
中科院分区：
文献类型：
--
作者：
Shuch, Brian;La Rochelle, Jeff C.;Belldegrun, Arie S.
背景。肾细胞癌脑转移（RCCBM）患者经常被排除在试验之外，据作者所知，目前尚无关于中枢神经系统（CNS）监测或治疗的指南。当前研究的目的是协助制定治疗指南。方法。确定了 1989 年至 2006 年间接受 RCCBM 评估的患者。对他们的特征、症状、病理变量、RCCBM 的数量和大小、CNS 治疗、CNS 复发、总生存率和全身治疗的使用进行了回顾。结果。共有 138 名患者被确诊为 RCCBM，其中 92% 患有透明细胞肾细胞癌，95% 患有同步颅外转移。 67% 的患者出现中枢神经系统症状。有症状的中枢神经系统肿瘤更大（2.1 cm vs 1.3 cm；P
BACKGROUND. Patients with renal cell carcinoma brain metastases (RCCBM) are frequently excluded from trials and to the authors' knowledge no guidelines currently exist regarding central nervous system (CNS) surveillance or treatment. The objective of the current study was to assist in the creation of treatment guidelines.METHODS. Patients undergoing evaluation for RCCBM from 1989 to 2006 were identified. Their characteristics, symptoms, pathologic variables, number and size of RCCBM, CNS treatment, CNS recurrence, overall survival, and use of systemic therapy were reviewed.RESULTS. A total of 138 patients were identified with RCCBM, of whom 92% had clear cell RCC and 95% had synchronous extracranial metastases. CNS symptoms were noted in 67% of patients. Symptomatic CNS tumors were larger (2.1 cm vs 1.3 cm; P